Erratum to Hyporesponsiveness to Erythropoietin: Causes and Management (DOI:10.1053/j.ackd.2008.12.004);Hyporesponsiveness to Erythropoietin: Causes and Management

Advances in Chronic Kidney Disease

Volumn 16, Issue 2, 2009, Pages 94-100

  Elliott, James ^a   Mishler, Dennis ^a   Agarwal, Rajiv ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; Chronic kidney disease; Erythropoietin; Inflammation; Iron

Indexed keywords

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; CITRIC ACID; CYANOCOBALAMIN; DEFEROXAMINE; FOLIC ACID; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ALUMINUM OVERLOAD; ANEMIA; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; CHRONIC KIDNEY FAILURE; DIALYSATE; DIALYSIS CATHETER; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG MEGADOSE; ERYTHROPOIESIS; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINOPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPARATHYROIDISM; IRON THERAPY; KIDNEY ALLOGRAFT; MALNUTRITION; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PERIODONTAL DISEASE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; QUALITY OF LIFE; THERAPY RESISTANCE; TREATMENT OUTCOME; UREMIA; WATER CONTAMINATION;

EID: 60149089000     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2009.10.001     Document Type: Erratum

References (53)

1. Del V.L., Pozzoni P., Andrulli S., et al. Inflammation and resistance to treatment with recombinant human erythropoietin. J Ren Nutr 15 (2005) 137-141
2. Kalantar-Zadeh K., Ikizler T.A., Block G., et al. Malnutrition-inflammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis 42 (2003) 864-881
3. Kalantar-Zadeh K., McAllister C.J., Lehn R.S., et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42 (2003) 761-773
4. Kalantar-Zadeh K., Rodriguez R.A., and Humphreys M.H. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 19 (2004) 141-149
5. Agarwal R., Davis J.L., and Smith L. Serum albumin is strongly associated with erythropoietin sensitivity in hemodialysis patients. Clin J Am Soc Nephrol 3 (2008) 98-104
6. Keithi-Reddy S.R., Addabbo F., Patel T.V., et al. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int 74 (2008) 782-790
7. Szczech L.A., Barnhart H.X., Inrig J.K., et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74 (2008) 791-798
8. Rahmati M.A., Craig R.G., Homel P., et al. Serum markers of periodontal disease status and inflammation in hemodialysis patients. Am J Kidney Dis 40 (2002) 983-989
9. Kadiroglu A.K., Kadiroglu E.T., Sit D., et al. Periodontitis is an important and occult source of inflammation in hemodialysis patients. Blood Purif 24 (2006) 400-404
10. Kreuzer K.A., Rockstroh J.K., Jelkmann W., et al. Inadequate erythropoietin response to anaemia in HIV patients: relationship to serum levels of tumour necrosis factor-alpha, interleukin-6 and their soluble receptors. Br J Haematol 96 (1997) 235-239
11. Kreuzer K.A., and Rockstroh J.K. Pathogenesis and pathophysiology of anemia in HIV infection. Ann Hematol 75 (1997) 179-187
12. Sipsas N.V., Kokori S.I., Ioannidis J.P., et al. Circulating autoantibodies to erythropoietin are associated with human immunodeficiency virus type 1-related anemia. J Infect Dis 180 (1999) 2044-2047
13. Mimic-Oka J., Simic T., Djukanovic L., et al. Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol 51 (1999) 233-241
14. Loughrey C.M., Young I.S., Lightbody J.H., et al. Oxidative stress in haemodialysis. QJM 87 (1994) 679-683
15. Ceballos-Picot I., Witko-Sarsat V., Merad-Boudia M., et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med 21 (1996) 845-853
16. Witko-Sarsat V., Friedlander M., Nguyen K.T., et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161 (1998) 2524-2532
17. Ifudu O., Feldman J., and Friedman E.A. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 334 (1996) 420-425
18. Movilli E., Cancarini G.C., Vizzardi V., et al. Epoetin requirement does not depend on dialysis dose when Kt/N > 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores. J Nephrol 16 (2003) 546-551
19. Walsh M., Culleton B., Tonelli M., et al. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int 67 (2005) 1500-1508
20. Sitter T., Bergner A., and Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 15 (2000) 1207-1211
21. Molina M., Navarro M.J., Palacios M.E., et al. [Importance of ultrapure dialysis liquid in response to the treatment of renal anaemia with darbepoetin in patients receiving haemodialysis]. Nefrologia 27 (2007) 196-201
22. Richardson D. Clinical factors influencing sensitivity and response to epoetin. Nephrol Dial Transplant 17 Suppl 1 (2002) 53-59
23. Richardson D., Bartlett C., Goutcher E., et al. Erythropoietin resistance due to dialysate chloramine: The two-way traffic of solutes in haemodialysis. Nephrol Dial Transplant 14 (1999) 2625-2627
24. Roberts T.L., Obrador G.T., St Peter W.L., et al. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int 66 (2004) 2429-2436
25. Goicoechea M., Caramelo C., Rodriguez P., et al. Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis. Nephrol Dial Transplant 16 (2001) 2188-2193
26. Nassar G.M., and Ayus J.C. Infectious complications of old nonfunctioning arteriovenous grafts in renal transplant recipients: A case series. Am J Kidney Dis 40 (2002) 832-836
27. Hasper D., Hummel M., Kleber F.X., et al. Systemic inflammation in patients with heart failure. Eur Heart J 19 (1998) 761-765
28. Anker S.D., and Coats A.J. Cardiac cachexia: A syndrome with impaired survival and immune and neuroendocrine activation. Chest 115 (1999) 836-847
29. Niebauer J., Volk H.D., Kemp M., et al. Endotoxin and immune activation in chronic heart failure: A prospective cohort study. Lancet 353 (1999) 1838-1842
30. Basile C., Lacour B., Drueke T., et al. Parathyroid function and erythrocyte production in the rat. Miner Electrolyte Metab 7 (1982) 197-206
31. Meytes D., Bogin E., Ma A., et al. Effect of parathyroid hormone on erythropoiesis. J Clin Invest 67 (1981) 1263-1269
32. Rao D.S., Shih M.S., and Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328 (1993) 171-175
33. Barbour G.L. Effect of parathyroidectomy on anemia in chronic renal failure. Arch Intern Med 139 (1979) 889-891
34. Boxer M., Ellman L., Geller R., et al. Anemia in primary hyperparathyroidism. Arch Intern Med 137 (1977) 588-593
35. Zingraff J., Drueke T., Marie P., et al. Anemia and secondary hyperparathyroidism. Arch Intern Med 138 (1978) 1650-1652
36. Wu S.G., Jeng F.R., Wei S.Y., et al. Red blood cell osmotic fragility in chronically hemodialyzed patients. Nephron 78 (1998) 28-32
37. Chow T.L., Chan T.T., Ho Y.W., et al. Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis. Arch Surg 142 (2007) 644-648
38. Urena P., Eckardt K.U., Sarfati E., et al. Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: Effect of parathyroidectomy. Nephron 59 (1991) 384-393
39. Alfrey A.C., LeGendre G.R., and Kaehny W.D. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 294 (1976) 184-188
40. Alfrey A.C. Aluminum toxicity in patients with chronic renal failure. Ther Drug Monit 15 (1993) 593-597
41. Kaehny W.D., Alfrey A.C., Holman R.E., et al. Aluminum transfer during hemodialysis. Kidney Int 12 (1977) 361-365
42. Donnelly S.M., Ali M.A., and Churchill D.N. Bioavailability of iron in hemodialysis patients treated with erythropoietin: Evidence for the inhibitory role of aluminum. Am J Kidney Dis 16 (1990) 447-451
43. Caramelo C.A., Cannata J.B., Rodeles M.R., et al. Mechanisms of aluminum-induced microcytosis: Lessons from accidental aluminum intoxication. Kidney Int 47 (1995) 164-168
44. Mladenovic J. Aluminum inhibits erythropoiesis in vitro. J Clin Invest 81 (1988) 1661-1665
45. Bia M.J., Cooper K., Schnall S., et al. Aluminum induced anemia: Pathogenesis and treatment in patients on chronic hemodialysis. Kidney Int 36 (1989) 852-858
46. Yaqoob M., Ahmad R., McClelland P., et al. Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy. Postgrad Med J 69 (1993) 124-128
47. Croizat H., and Nagel R.L. Circulating cytokines response and the level of erythropoiesis in sickle cell anemia. Am J Hematol 60 (1999) 105-115
48. Casadevall N., Nataf J., Viron B., et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346 (2002) 469-475
49. Kalantar-Zadeh K., Kalantar-Zadeh K., and Lee G.H. The fascinating but deceptive ferritin: To measure it or not to measure it in chronic kidney disease?. Clin J Am Soc Nephrol 1 Suppl 1 (2006) S9-S18
50. Kinney R. 2005 Annual Report: ESRD Clinical Performance Measures Project. Am J Kidney Dis 48 (2006) S1-S106
51. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 (2006) S11-S145
52. Coyne D.W., Kapoian T., Suki W., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 (2007) 975-984
53. Kapoian T., O'Mara N.B., Singh A.K., et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 19 (2008) 372-379